LT3365B - Vaccine for human immunodeficiency virus - Google Patents

Vaccine for human immunodeficiency virus Download PDF

Info

Publication number
LT3365B
LT3365B LTIP335A LTIP335A LT3365B LT 3365 B LT3365 B LT 3365B LT IP335 A LTIP335 A LT IP335A LT IP335 A LTIP335 A LT IP335A LT 3365 B LT3365 B LT 3365B
Authority
LT
Lithuania
Prior art keywords
hiv
recombinant
vaccine
protein
composition
Prior art date
Application number
LTIP335A
Other languages
English (en)
Lithuanian (lt)
Inventor
Gale E Smith
Franklin Volvovitz
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of LTIP335A publication Critical patent/LTIP335A/xx
Publication of LT3365B publication Critical patent/LT3365B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTIP335A 1991-06-11 1993-02-11 Vaccine for human immunodeficiency virus LT3365B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (2)

Publication Number Publication Date
LTIP335A LTIP335A (en) 1995-01-31
LT3365B true LT3365B (en) 1995-07-25

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP335A LT3365B (en) 1991-06-11 1993-02-11 Vaccine for human immunodeficiency virus

Country Status (18)

Country Link
EP (1) EP0542998A1 (et)
JP (1) JPH06501851A (et)
CN (1) CN1068266A (et)
AU (2) AU2193192A (et)
BG (1) BG97519A (et)
CA (1) CA2087732A1 (et)
EE (1) EE9400183A (et)
FI (1) FI930577L (et)
HU (1) HUT68355A (et)
IE (1) IE921875A1 (et)
IL (1) IL102092A (et)
LT (1) LT3365B (et)
MX (1) MX9202781A (et)
PL (1) PL297849A1 (et)
PT (1) PT100584A (et)
SK (1) SK18993A3 (et)
WO (1) WO1992022654A1 (et)
ZA (1) ZA924150B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1995017515A1 (en) * 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
AU2012298125B2 (en) 2011-08-19 2015-09-24 Immortal Spirit Limited Antibody and antibody-containing composition
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BARIN F.: "Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients", SCIENCE, 1985, pages 1094 - 1096, XP000916624, DOI: doi:10.1126/science.2986291
BARRÉ-SINOUSSI F. ET AL.: "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)", SCIENCE, 1983, pages 868 - 871, XP008006485, DOI: doi:10.1126/science.6189183
BURKE ET AL.: "Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group.", J ACQUIR IMMUNE DEFIC SYNDR, 1991, pages 1159 - 1167
CHAKRABARTI S. ET AL.: "Expression of the HTLV-envelope gene by a recombinant vaccinia virus", NATURE, 1986, pages 535 - 537
FEORINO P.M. ET AL.: "Lymphadenopathy associated virus infection of a blood donor--recipient pair with acquired immunodeficiency syndrome", SCIENCE, 1984, pages 69 - 72
FRANCIS D.P. AND PETRICCIANI J.C.: "The Prospects for and Pathways toward a Vaccine for AIDS", NEW ENG.J.MED., 1985, pages 1586 - 1590
HU S.L. ET AL.: "Expression of AIDS Virus Envelope Gene in Recombinant Vaccinia Viruses", NATURE, 1986, pages 537 - 540
KIENY M.P ET AL.: "AIDS virus env protein expressed from vaccinia virus", BIOTECHNOLOGY, 1986, pages 790 - 795, XP009011051, DOI: doi:10.1038/nbt0986-790
LASKY L.A. ET AL.: "Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein", SCIENCE, 1986, pages 209 - 212
LEVY J.A.: "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS", SCIENCE, 1984, pages 840 - 842
POPOVIC M. ET AL.: "Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS", SCIENCE, 1984, pages 497 - 500, XP001154353, DOI: doi:10.1126/science.6200935
PUTNEY S.D. ET AL.: "HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope", SCIENCE, 1986, pages 1392 - 1395, XP002067356, DOI: doi:10.1126/science.2431482
RADFIELD R.R. ET AL.: "The Walter Reed Staging Classification for HTLV-III/LAV Infection", NEW ENG.J.MED., 1986, pages 131 - 132
ROBEY W.G. ET AL.: "Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody", PROC NATL ACAD SCI U S A., 1986, pages 7023 - 7027, XP002129495, DOI: doi:10.1073/pnas.83.18.7023
VOGT M AND HIRSH M.S.: "Prospects for the Prevention and Therapy on Infections with the Human Immunodeficiency Virus", REWIEWS OF INFECTIOUS DISEASE, 1986, pages 991 - 1000
WAGES J.M. ET AL.: "Clinical performance of a polymerase chain reaction testing algorithm for diagnosis of HIV-1 infection in peripheral blood mononuclear cells", J. MED. VIROL., 1991, pages 58 - 63

Also Published As

Publication number Publication date
SK18993A3 (en) 1993-10-06
FI930577A7 (fi) 1993-03-24
MX9202781A (es) 1993-04-01
HU9300686D0 (en) 1993-06-28
IL102092A0 (en) 1993-01-14
AU4028895A (en) 1996-02-22
EE9400183A (et) 1995-12-15
HUT68355A (en) 1995-06-28
LTIP335A (en) 1995-01-31
AU2193192A (en) 1993-01-12
PL297849A1 (en) 1994-01-24
BG97519A (bg) 1994-03-24
JPH06501851A (ja) 1994-03-03
IL102092A (en) 1996-11-14
ZA924150B (en) 1993-02-24
PT100584A (pt) 1993-07-30
FI930577A0 (fi) 1993-02-10
IE921875A1 (en) 1992-12-16
CA2087732A1 (en) 1992-12-12
FI930577L (fi) 1993-03-24
WO1992022654A1 (en) 1992-12-23
EP0542998A1 (en) 1993-05-26
CN1068266A (zh) 1993-01-27

Similar Documents

Publication Publication Date Title
LT3365B (en) Vaccine for human immunodeficiency virus
AU732809B2 (en) Compositions and methods for treating viral infections
EP0546787A2 (en) Expression of specific immunogens using viral antigens
CH675728A5 (et)
Karpenko et al. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine: Design, immunogenicity and toxicity studies
EP0327180A2 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
Levi et al. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
US6290963B1 (en) Anti-HIV compositions containing native and recombinant peptides
HRP921484A2 (en) Vaccine and treatment method of human immunodeficiency virus infection
AU2006200454B2 (en) Compositions and methods for treating viral infections
SI9200420A (sl) Vakcina proti infekciji, ki jo povzroča človeški virus imunodeficience
Berman et al. Production of Viral Glycoproteins in Genetically Engineered Mammalian Cell Lines for Use as Vaccines against Herpes Simplex Virus and the Acquired Immune Deficiency Syndrome Retrovirus
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
HU211505A9 (hu) HIV-fertőzés kezelésére szolgáló vakcinakészítmény Az átmeneti oltalom az 1-15. igénypontokra vonatkozik.
LV10492B (en) Vaccine and treatment method for human immunodeficiency virus
LV10497B (en) A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene
WO1998001570A2 (en) Mutated antibody-dependent infection enhancing domains of hiv
AU2004201321A1 (en) Compositions and methods for treating viral infections
DD283936A5 (de) Verfahren zur herstellung von peptiden, die in der lage sind immunologisch die neutralisierenden bereiche von hiv proteinen nachzuahmen
AU2004208648A1 (en) Compositions and methods for treating infections

Legal Events

Date Code Title Description
TK9A Rectifications: patents

Free format text: 11. KOMPOZICIJA PAGAL 8 PUNKTA, B E S I S K I R I A N T I TUO, KAD REKOMBINANTINIS BALTYMAS SUDARYTAS IS APYTIKSLIAI 757 GP160 VIENA PO KITOS EINANCIU AMINORUGSCIU IR KURIAME VISISKAI PASALINTA APYTIKSLIAI 40 VIENA PO KITOS EINANCIU GALINIU AMINORUGSCIU., 19950815

MM9A Lapsed patents

Effective date: 19960211